New 3D method may improve tumor measurement accuracy
NCT ID NCT07319767
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 120 adults with breast, pancreatic, or biliary cancer to see if a new 3D measurement method (TDTP-RECIST) is better than the standard way (RECIST 1.1) for tracking tumor shrinkage before surgery. Researchers compared imaging results with actual tumor tissue removed during surgery. The goal is to help doctors choose more accurate tools for assessing treatment response in irregularly shaped tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY CANCER (CHOLANGIOCARCINOMA, GALL BLADDER CANCER) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zhongshan Hospital, Fudan University
Shanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can pancreatic Cancer's inflammatory footprint be stopped?
- Can sound waves supercharge immunotherapy against bile duct cancer?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?